ערך בספרים למניה: PharmaCyte Biotech, Inc. (PMCB)

PharmaCyte Biotech (PMCB) faces a high binary outcome risk due to its narrow specialization in a single technology, coupled with pressure from alternative immuno-oncology platforms. Data on GURU.Markets regarding the stock's book value reflects the asset's dynamics, where the current level is 2.55. The innovative "cell-in-a-box" method enables targeted action against pancreatic tumors, significantly reducing therapy toxicity and improving patient survival rates.

For PharmaCyte Biotech (PMCB), which is developing the unique CypCaps technology and conducting clinical trials in oncology, this indicator serves as a measure of the real value of assets. The calculation is performed by dividing the difference between total assets and liabilities by the number of shares, while the visualization of the book value per share allows for the daily tracking of equity dynamics to assess the financial stability of the biotechnology business.